Literature DB >> 32930456

Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex.

Aaron C Petrey1,2, Fares Qeadan3, Elizabeth A Middleton1,4, Irina V Pinchuk5, Robert A Campbell1,4, Ellen J Beswick2,4.   

Abstract

COVID-19 rapidly emerged as a crippling public health crisis in the last few months, which has presented a series health risk. Understanding of the immune response and biomarker analysis is needed to progress toward understanding disease pathology and developing improved treatment options. The goal of this study is to identify pathogenic factors that are linked to disease severity and patient characteristics. Patients with COVID-19 who were hospitalized from March 17 to June 5, 2020 were analyzed for clinical features of disease and soluble plasma cytokines in association with disease severity and sex. Data from COVID-19 patients with acute illness were examined along with an age- and gender-matched control cohort. We identified a group of 16 soluble factors that were found to be increased in COVID-19 patients compared to controls, whereas 2 factors were decreased. In addition to inflammatory cytokines, we found significant increases in factors known to mediate vasculitis and vascular remodeling (PDGF-AA, PDGF-AB-BB, soluble CD40L (sCD40L), FGF, and IP10). Four factors such as platelet-derived growth factors, fibroblast growth factor-2, and IFN-γ-inducible protein 10 were strongly associated with severe disease and ICU admission. Th2-related factors (IL-4 and IL-13) were increased with IL-4 and sCD40L present at increased levels in males compared with females. Our analysis revealed networking clusters of cytokines and growth factors, including previously unknown roles of vascular and stromal remodeling, activation of the innate immunity, as well activation of type 2 immune responses in the immunopathogenesis of COVID-19. These data highlight biomarker associations with disease severity and sex in COVID-19 patients. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:     

Mesh:

Substances:

Year:  2020        PMID: 32930456      PMCID: PMC7902354          DOI: 10.1002/JLB.3COVA0820-410RRR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  51 in total

Review 1.  Interactions between extracellular matrix and growth factors in wound healing.

Authors:  Gregory S Schultz; Annette Wysocki
Journal:  Wound Repair Regen       Date:  2009 Mar-Apr       Impact factor: 3.617

2.  A novel cytokine profile associated with cancer metastasis to mediastinal and hilar lymph nodes identified using fine needle aspiration biopsy - A pilot study.

Authors:  Ali I Saeed; Fares Qeadan; Akshay Sood; Dorothy J VanderJagt; Shiraz I Mishra; Deirdre A Hill; Tobias Peikert; Mohan L Sopori
Journal:  Cytokine       Date:  2016-09-03       Impact factor: 3.861

3.  Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.

Authors:  Lorenzo D'Antiga
Journal:  Liver Transpl       Date:  2020-04-24       Impact factor: 5.799

4.  Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury.

Authors:  Mihail Hristov; Denis Gümbel; Esther Lutgens; Alma Zernecke; Christian Weber
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

5.  Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.

Authors:  Y Guan; B J Zheng; Y Q He; X L Liu; Z X Zhuang; C L Cheung; S W Luo; P H Li; L J Zhang; Y J Guan; K M Butt; K L Wong; K W Chan; W Lim; K F Shortridge; K Y Yuen; J S M Peiris; L L M Poon
Journal:  Science       Date:  2003-09-04       Impact factor: 47.728

6.  Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.

Authors:  Han Zhu; June-Wha Rhee; Paul Cheng; Sarah Waliany; Amy Chang; Ronald M Witteles; Holden Maecker; Mark M Davis; Patricia K Nguyen; Sean M Wu
Journal:  Curr Cardiol Rep       Date:  2020-05-13       Impact factor: 2.931

7.  Signals of Th2 immune response from COVID-19 patients requiring intensive care.

Authors:  Luca Roncati; Vincenzo Nasillo; Beatrice Lusenti; Giovanni Riva
Journal:  Ann Hematol       Date:  2020-05-08       Impact factor: 3.673

8.  Type 3 hypersensitivity in COVID-19 vasculitis.

Authors:  Luca Roncati; Giulia Ligabue; Luca Fabbiani; Claudia Malagoli; Graziana Gallo; Beatrice Lusenti; Vincenzo Nasillo; Antonio Manenti; Antonio Maiorana
Journal:  Clin Immunol       Date:  2020-05-29       Impact factor: 3.969

Review 9.  Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.

Authors:  Yvan Jamilloux; Thomas Henry; Alexandre Belot; Sébastien Viel; Maxime Fauter; Thomas El Jammal; Thierry Walzer; Bruno François; Pascal Sève
Journal:  Autoimmun Rev       Date:  2020-05-04       Impact factor: 9.754

10.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.

Authors:  Zhaohai Zheng; Fang Peng; Buyun Xu; Jingjing Zhao; Huahua Liu; Jiahao Peng; Qingsong Li; Chongfu Jiang; Yan Zhou; Shuqing Liu; Chunji Ye; Peng Zhang; Yangbo Xing; Hangyuan Guo; Weiliang Tang
Journal:  J Infect       Date:  2020-04-23       Impact factor: 6.072

View more
  40 in total

Review 1.  Immune Sexual Dimorphism: Connecting the Dots.

Authors:  Shani Talia Gal-Oz; Tal Shay
Journal:  Physiology (Bethesda)       Date:  2021-09-13

Review 2.  PI3K Signaling in Mechanisms and Treatments of Pulmonary Fibrosis Following Sepsis and Acute Lung Injury.

Authors:  Jean Piero Margaria; Lucia Moretta; Jose Carlos Alves-Filho; Emilio Hirsch
Journal:  Biomedicines       Date:  2022-03-23

3.  SARS-CoV-2 infection- induced growth factors play differential roles in COVID-19 pathogenesis.

Authors:  Anamika Gupta; Manju N Jayakumar; Mohamed A Saleh; Meganathan Kannan; Rabih Halwani; Rizwan Qaisar; Firdos Ahmad
Journal:  Life Sci       Date:  2022-06-11       Impact factor: 6.780

Review 4.  Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.

Authors:  Alexandra Pum; Maria Ennemoser; Tiziana Adage; Andreas J Kungl
Journal:  Biomolecules       Date:  2021-01-12

Review 5.  Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients.

Authors:  Subrata Deb; Scott Arrighi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

Review 6.  Implications of microscale lung damage for COVID-19 pulmonary ventilation dynamics: A narrative review.

Authors:  Elizabeth Dimbath; Veeranna Maddipati; Jennifer Stahl; Kerry Sewell; Zachary Domire; Stephanie George; Ali Vahdati
Journal:  Life Sci       Date:  2021-03-11       Impact factor: 6.780

7.  Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4.

Authors:  Madhavi P Gavini; Abuzar Mahmood; Anthony M Belenchia; Paige Beauparlant; Senthil A Kumar; Sivakumar Ardhanari; Vincent G DeMarco; Lakshmi Pulakat
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

8.  Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI.

Authors:  Fabian Bohländer; Dennis Riehl; Sabrina Weißmüller; Marcus Gutscher; Jörg Schüttrumpf; Stefanie Faust
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

9.  Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.

Authors:  Xiang-Zhi Fang; Ya-Xin Wang; Ji-Qain Xu; Ya-Jun He; Zhe-Kang Peng; You Shang
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

10.  Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.

Authors:  Amanda J Griffin; Kyle L O'Donnell; Kyle Shifflett; John-Paul Lavik; Patrick M Russell; Michelle K Zimmerman; Ryan F Relich; Andrea Marzi
Journal:  Sci Rep       Date:  2022-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.